Literature DB >> 12529665

Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study.

P Korkolopoulou1, N Viniou, N Kavantzas, E Patsouris, I Thymara, P M Pavlopoulos, E Terpos, K Stamatopoulos, E Plata, K Anargyrou, A Androulaki, P Davaris, X Yataganas.   

Abstract

Various morphometric characteristics of microvessels, highlighted by means of anti-CD34 immunohistochemical staining, were evaluated in the bone marrow of 52 patients with chronic myeloid leukemia (CML) in chronic phase, in relation to several clinicopathologic parameters. Twenty control bone marrows and 15 cases of CML in blastic phase were also studied. Microvessel density (MVD), total vascular area (TVA) and several size- and shape-related parameters were quantitated in the region of most intense vascularization using image analysis. Overall, the group of chronic phase CML had higher MVD and size-related parameters and more branching microvessels than controls. Blastic phase was characterized by increased numbers of microvessels with a rounder shape and smaller caliber than chronic phase. A positive correlation emerged between marrow fibrosis and MVD as well as between white blood cell counts and rounder vessel sections. No relationship existed between microvascular parameters and Hasford or Sokal prognostic scores. In univariate analysis, overall and progression-free survival were adversely affected by MVD, size-related parameters, increased platelet count, age and spleen size. Multivariate analysis indicated that microvessel area was related to progression-free survival, whereas both MVD and area were significant prognosticators of overall survival, even when Hasford or Sokal scores are introduced into the model. Our data suggest that changes in angiogenic parameters may participate in the conversion of normal marrow to CML and ultimately to blastic transformation. More importantly, MVD and microvessel caliber are significant predictors of patient survival and progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12529665     DOI: 10.1038/sj.leu.2402769

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

1.  Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia.

Authors:  Fang Zheng; Huiyu Li; Kaiwei Liang; Yimei Du; Dongmei Guo; Shiang Huang
Journal:  Med Oncol       Date:  2011-12-10       Impact factor: 3.064

2.  Angiogenic patterns and their quantitation in high grade astrocytic tumors.

Authors:  Suash Sharma; Mehar C Sharma; Deepak Kumar Gupta; Chitra Sarkar
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

3.  The Local HIF-2α/EPO Pathway in the Bone Marrow is Associated with Excessive Erythrocytosis and the Increase in Bone Marrow Microvessel Density in Chronic Mountain Sickness.

Authors:  Juan Su; Zhanquan Li; Sen Cui; Linhua Ji; Hui Geng; Kexia Chai; Xiaojing Ma; Zhenzhong Bai; Yingzhong Yang; Tana Wuren; Ri-Li Ge; Matthew T Rondina
Journal:  High Alt Med Biol       Date:  2015-12-01       Impact factor: 1.981

4.  TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

Authors:  E Nievergall; J Reynolds; C H Kok; D B Watkins; M Biondo; S J Busfield; G Vairo; K Fuller; W N Erber; T Sadras; R Grose; D T Yeung; A F Lopez; D K Hiwase; T P Hughes; D L White
Journal:  Leukemia       Date:  2016-02-22       Impact factor: 11.528

5.  Improved prediction of clinical outcome in chronic myeloid leukemia.

Authors:  Irena Ćojbašić; Lana Mačukanović-Golubović; Dragan Mihailović; Miodrag Vučić; Stevo Lukić
Journal:  Int J Hematol       Date:  2014-12-25       Impact factor: 2.490

6.  PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia.

Authors:  Yüksel Filik; Karin Bauer; Emir Hadzijusufovic; Patrick Haider; Georg Greiner; Nadine Witzeneder; Gregor Hoermann; Philipp J Hohensinner; Karoline V Gleixner; Johann Wojta; Wolfgang R Sperr; Peter Valent
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 7.  Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies.

Authors:  Md Salman Shakil; Mahruba Sultana Niloy; Kazi Mustafa Mahmud; Mohammad Amjad Kamal; Md Asiful Islam
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

8.  A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.

Authors:  Shannon K McWeeney; Lucy C Pemberton; Marc M Loriaux; Kristina Vartanian; Stephanie G Willis; Gregory Yochum; Beth Wilmot; Yaron Turpaz; Raji Pillai; Brian J Druker; Jennifer L Snead; Mary MacPartlin; Stephen G O'Brien; Junia V Melo; Thoralf Lange; Christina A Harrington; Michael W N Deininger
Journal:  Blood       Date:  2009-10-16       Impact factor: 22.113

Review 9.  Extracellular vesicle-mediated cell-cell communication in haematological neoplasms.

Authors:  Junko H Ohyashiki; Tomohiro Umezu; Kazuma Ohyashiki
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-05       Impact factor: 6.237

10.  Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis.

Authors:  C R T Godoy; D Levy; V Giampaoli; D A F Chamone; S P Bydlowski; J Pereira
Journal:  Braz J Med Biol Res       Date:  2015-03-27       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.